Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

Plasma genotyping identifies potentially actionable mutations at variable mutant allele frequencies, often admixed with multiple subclonal variants, highlighting the need for their clinical and functional validation. We prospectively monitored plasma genotypes in 143 women with endocrine-resistant m...

Descripción completa

Detalles Bibliográficos
Autores principales: Medford, Arielle J., Dubash, Taronish D., Juric, Dejan, Spring, Laura, Niemierko, Andrzej, Vidula, Neelima, Peppercorn, Jeffrey, Isakoff, Steven, Reeves, Brittany A., LiCausi, Joseph A., Wesley, Benjamin, Malvarosa, Giuliana, Yuen, Megan, Wittner, Ben S., Lawrence, Michael S., Iafrate, A. John, Ellisen, Leif, Moy, Beverly, Toner, Mehmet, Maheswaran, Shyamala, Haber, Daniel A., Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635494/
https://www.ncbi.nlm.nih.gov/pubmed/31341951
http://dx.doi.org/10.1038/s41698-019-0090-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635494/
https://www.ncbi.nlm.nih.gov/pubmed/31341951
http://dx.doi.org/10.1038/s41698-019-0090-5

Ejemplares similares